{"id":"NCT05178810","sponsor":"Ferrer Internacional S.A.","briefTitle":"Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-18","primaryCompletion":"2023-10-26","completion":"2023-10-26","firstPosted":"2022-01-05","resultsPosted":"2025-03-18","lastUpdate":"2025-03-18"},"enrollment":313,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"FAB122","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"FAB122","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.","primaryOutcome":{"measure":"Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score After 48 Weeks.","timeFrame":"48 weeks","effectByArm":[{"arm":"FAB122","deltaMin":-11.2,"sd":7.9},{"arm":"Placebo","deltaMin":-10.8,"sd":8.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":38,"countries":["Belgium","France","Germany","Ireland","Italy","Netherlands","Poland","Portugal","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":62,"n":205},"commonTop":["Fall","COVID-19","Respiratory failure","Constipation","Dysphagia"]}}